112 - Latest European guidelines for dyslipidemias in the setting of familial hypercholesterolemia: data from the HELLAS-FH registry (ID 266)
- Christos Rizos, Greece
- Ioannis Skoumas, Greece
- Loukianos Rallidis, Greece
- Konstantinos Tziomalos, Greece
- Emmanuel Skalides, Greece
- Vasileios Kotsis, Greece
- Anastasia Garoufi, Greece
- Vasileios G. Athyros, Greece
- Genovefa Kolovou, Greece
- Georgios Sfikas, Greece
- Eleni Bilianou, Greece
- Iosif Koutagiar, Greece
- Estela Kiouri, Greece
- Dimitrios Agapakis, Greece
- Evangelos Zacharis, Greece
- Christina Antza, Greece
- Achilleas Attilakos, Greece
- Niki Katsiki, Greece
- Panagiotis Anagnostis, Greece
- Moses Elisaf, Greece
- Evangelos Liberopoulos, Greece
Abstract
Background and Aims
Familial hypercholesterolemia (FH) is the most common hereditary form of hypercholesterolemia and is strongly associated with cardiovascular disease. The latest European dyslipidemia guidelines (ESC/EAS 2019) recommend lower LDL cholesterol (LDL-C) treatment targets in patients with FH, i.e. <55 mg/dL if established cardiovascular disease or an additional risk factor and <70 mg/dL in all other patients. The aim of the study was to map the LDL-C target achievement based on the latest European guidelines for the management of dyslipidemia in adult patients enrolled in the HELLAS-FH registry.
Methods
A total 1633 adult patients with a clinical diagnosis of FH were evaluated. Demographics, drug treatment and lipid profile of patients were assessed.
Results
Patients were 52% male, 51.3±14.6 years old while the FH diagnosis age was 44.3±15.9 years. Patients at baseline had mean TCHOL 317±79 mg/dL and LDL-C 235±79 mg/dL. Most patients (70.7%) were already receiving hypolipidemic treatment at baseline. The majority of treated patients were receiving a statin (98.1%), almost half were receiving ezetimibe (48.1%) followed by other hypolipidemic treatment regimens. Treated patients had mean TCHOL values of 231±74 mg/dL and LDL-C 153±70 mg/dL. According to the latest European dyslipidemia guidelines, achievement rates of LDL-C targets were only 4.6% in all treated patients and 5.1% in those receiving high-intensity statin plus ezetimibe.
Conclusions
With the implementation of the latest European guidelines for the management of dyslipidemia, the number of FH patients reaching LDL-C targets is minimal even for those treated with high-intensity statin and ezetimibe.
